1. SH2B3 aberrations enriched in iAMP21 B lymphoblastic leukemia
- Author
-
Matthew M. Meredith, LeAnn Oseth, Teresa A. Smolarek, Linda B. Baughn, and Betsy A. Hirsch
- Subjects
Adult ,Male ,0301 basic medicine ,Cancer Research ,Adolescent ,Microarray ,Chromosomes, Human, Pair 21 ,Biology ,DNA sequencing ,Loss of heterozygosity ,Cytogenetics ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Genetics ,medicine ,Humans ,Child ,Molecular Biology ,Gene ,In Situ Hybridization, Fluorescence ,Adaptor Proteins, Signal Transducing ,Chromosome Aberrations ,Comparative Genomic Hybridization ,medicine.diagnostic_test ,Gene Amplification ,Intracellular Signaling Peptides and Proteins ,High-Throughput Nucleotide Sequencing ,Proteins ,Chromosome Banding ,030104 developmental biology ,RUNX1 ,chemistry ,Child, Preschool ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,Female ,Chromosome 21 ,Tyrosine kinase ,Fluorescence in situ hybridization - Abstract
Acute lymphoblastic leukemia (ALL) represents the most common childhood malignancy. Although survival for pediatric B-ALL has approached 90%, variability in outcome among and within cytogenetically defined subgroups persists. While G-banding and fluorescence in situ hybridization (FISH) have been used to characterize leukemic clones, there is added value of chromosomal microarray and next generation sequencing in screening genome-wide for copy number aberrations, copy neutral loss of heterozygosity and nucleotide variations. Evaluation of novel genetic aberrations can provide information about the biologic mechanisms of cytogenetically defined subgroups associated with poor prognosis, explain heterogeneity in patient outcome and identify novel targets for therapeutic intervention. The high risk B-ALL intrachromosomal amplification of chromosome 21, (iAMP21), subtype is characterized by amplification of a region of chromosome 21 that typically encompasses the RUNX1 gene and is associated with poor prognosis. Analysis of chromosomal microarray and FISH data revealed that deletions of SH2B3, encoding a negative regulator of multiple tyrosine kinase and cytokine signaling pathways, are enriched among leukemias harboring iAMP21. Enrichment of SH2B3 aberrations in the iAMP21 subtype may indicate that loss of SH2B3 contributes to disease progression and raises the possibility that these leukemias may be sensitive to tyrosine kinase inhibitors.
- Published
- 2018
- Full Text
- View/download PDF